Cinobac

• Anti-Infective Agents
• ATC:J01MB06

• Cinobac

• No information avaliable

C₁₂H₁₀N₂O₅

http://www.rxlist.com/cgi/generic3/cinobac.htm

Cinobac FDA

Cinobac MSDS

No information avaliable

262.218 g/mol

261 ^oC

No information avaliable

Solid

0.617

Capsules (250mg and 500mg)

For the treatment of initial and recurrent urinary tract infections in adults caused by the following susceptible microorganisms: Escherichia coli, Proteus mirabilis, Proteus vulgaris, Klebsiella species (including K. pneumoniae), and Enterobacter species.

Cinoxacin is a synthetic antibacterial agent with in vitro activity against many gram-negative aerobic bacteria, particularly strains of the Enterobacteriaceae family. Cinoxacin inhibits bacterial deoxyribonucleic acid (DNA) synthesis, is bactericidal, and is active over the entire urinary pH range. Cross resistance with nalidixic acid has been demonstrated.

Rapidly absorbed after oral administration. The presence of food delays absorption but does does not affect total absorption.

Oral, subcutaneous, and intravenous LD₅₀ in the rat is 3610 mg/kg, 1380 mg/kg, and 860 mg/kg, respectively. Oral, subcutaneous, and intravenous LD₅₀ in the mouse is 2330 mg/kg, 900 mg/kg, and 850 mg/kg, respectively.Symptoms following an overdose of cinoxacin may include anorexia, nausea, vomiting, epigastric distress, and diarrhea. The severity of the epigastric distress and the diarrhea are dose related. Headache, dizziness, insomnia, photophobia, tinnitus, and a tingling sensation have been reported in some patients.

Enteric bacteria and other eubacteria